← Leaderboards
George Saviolakis
Dynport Vaccine Company, Llc
$1,316,543
Attributed
$1,316,543
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $293.7K · FY2015–25$500K$375K$250K$125K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,316,543 · 2
By mechanism
N01$1,316,543 · 2
Top collaborators
No co-investigators on record.
Most similar at Dynport Vaccine Company, Llc
Same institution · by research overlap
- Graig Shockey$9,887,057
- Salama Balume$16,877,312
- David Shumway$6,214,596
- Casey Long$2,265,501
- Abraham Kallarkal$10,500
Others in their field
Top investigators on “Investigation”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$681,473,477
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$448,008,305
- Judith S. Currier · University Of California Los Angeles$395,422,692
Research focus
InvestigationClinical Trials UnitCommunicable DiseasesEarly Phase Clinical TrialPreventionNew AgentsNational Institute Of Allergy And Infectious DiseaseClinical Trial ImplementationClinical TrialsInfectious Disease TreatmentNovel TherapeuticsPhase I Clinical TrialsClinical Infrastructure
Grant awards (6)
Task A: Early Phase Clinical Trial Units (EPCTU)$215,604
N01 · FY2025 · AI · contact PI
Task A: Early Phase Clinical Trial Units (EPCTU)$212,105
N01 · FY2024 · AI · contact PI
Early Phase Clinical Trial Units$208,820
N01 · FY2023 · AI · contact PI
Early Phase Clinical Trial Units$172,910
N01 · FY2022 · AI · contact PI
Phase I Clinical Trial Unit for Therapeutics$213,438
N01 · FY2016 · AI · contact PI
Phase I Clinical Trial Units$293,666
N01 · FY2015 · AI · contact PI